^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ET-02

    i
    Other names: ET-02, CD19-UCART
    Associations

    News

    Trials
    Company:
    EdiGene
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL) (clinicaltrials.gov)
    P=N/A, N=18, Active, not recruiting, EdiGene (GuangZhou) Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • ET-02